Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SARS-CoV-2 infection in HIV-infected patients: potential role in the high mutational load of the Omicron variant emerging in South Africa. | Geroscience | 2022 | 35739343 | PubTator, text mining | PubMed |
| Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. | J Med Chem | 2022 | 35731933 | PubTator, text mining | PubMed |
| Expression Profile and Localization of SARS-CoV-2 Nonstructural Replicase Proteins in Infected Cells. | Microbiol Spectr | 2022 | 35730969 | PubTator, text mining | PubMed |
| Structural, genomic information and computational analysis of emerging coronavirus (SARS-CoV-2). | Bull Natl Res Cent | 2022 | 35729950 | PubTator, text mining | PubMed |
| Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. | Nat Commun | 2022 | 35729165 | PubTator, text mining | PubMed |
| Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. | Elife | 2022 | 35723575 | PubTator, text mining | PubMed |
| Transcription of the Envelope Protein by 1-L Protein-RNA Recognition Code Leads to Genes/Proteins That Are Relevant to the SARS-CoV-2 Life Cycle and Pathogenesis. | Curr Issues Mol Biol | 2022 | 35723340 | PubTator, text mining | PubMed |
| Genome-Wide Analysis of the Indispensable Role of Non-structural Proteins in the Replication of SARS-CoV-2. | Front Microbiol | 2022 | 35722274 | PubTator, text mining | PubMed |
| Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteins-A Possible Signature of Adaptive Selection. | Front Genet | 2022 | 35719386 | PubTator, text mining | PubMed |
| Mutations of the SARS-CoV-2 Spike Glycoprotein Detected in Cats and Their Effect on Its Structure and Function. | Front Cell Infect Microbiol | 2022 | 35719353 | PubTator, text mining | PubMed |
| SARS-CoV-2: phenotype, genotype, and characterization of different variants. | Cell Mol Biol Lett | 2022 | 35715738 | PubTator, text mining | PubMed |
| A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants. | Nat Commun | 2022 | 35715395 | PubTator, text mining | PubMed |
| Prediction of the effects of the top 10 nonsynonymous variants from 30229 SARS-CoV-2 strains on their proteins. | F1000Res | 2022 | 35707000 | PubTator, text mining | PubMed |
| Molecular modelling and simulation techniques to investigate the effects of fungal metabolites on the SARS-CoV-2 RdRp protein inhibition. | J King Saud Univ Sci | 2022 | 35702575 | PubTator, text mining | PubMed |
| Re-Examining Rotavirus Innate Immune Evasion: Potential Applications of the Reverse Genetics System. | mBio | 2022 | 35699371 | PubTator, text mining | PubMed |
| Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. | Signal Transduct Target Ther | 2022 | 35697684 | PubTator, text mining | PubMed |
| The potential role of COVID-19 in the induction of DNA damage. | Mutat Res Rev Mutat Res | 2022 | 35690420 | PubTator, text mining | PubMed |
| The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. | Microb Pathog | 2022 | 35690234 | PubTator, text mining | PubMed |
| Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. | Toxicol Appl Pharmacol | 2022 | 35688186 | PubTator, text mining | PubMed |
| Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. | Int J Mol Sci | 2022 | 35682761 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=49